|28th February 2020
The right kind of insight can help pharmaceutical and healthcare companies to be truly customer-centred and data-driven. It can provide a holistic understanding of customers and different aspects of their lives that likely affect their interaction with the business. For example, met and unmet needs, how they think and feel, what they value most, and what drives their decision-making process.
That’s why collecting the right data and extracting the right insight to inform your actions can show you how to best address real customer needs seamlessly.
There is still some confusion around the difference between data and insight. At Blue Latitude Health, we define data as the raw and often unprocessed evidence, which normally takes the form of numbers and text.
Insights are extracted through the process of data analysis. We interpret the data with the context and objective of its use in mind to draw conclusions and form meaningful, actionable ‘nuggets’ – insights.
The insight you extract from your data shouldn’t be ‘static’, or a single-use, onetime view of your customers, regardless of whether they are healthcare professionals, patients or caregivers. Your customers evolve; the landscape and context in which they operate changes, and so should your insight. In that regard, even the fact that your insights are changing (or not) is a valuable insight in itself.
Generating insight is often expensive, which means it is essential to ensure the insights commissioned in one project can drive future strategies. However, in many cases, the ROI of the commissioned research is suboptimal. This is due to the negative insight lifecycle – a trap pharmaceutical and healthcare companies often fall into. This cycle results in insight being difficult to communicate, easily disregarded or stored somewhere on a server and forgotten.
|27th March 2020
Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.
|6th March 2020
BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.
|28th February 2020
Pharmaceutical and healthcare companies invest a great deal of time and money in commissioning research to address their insight gaps. The process often results in suboptimal return on investment (ROI) due to faulty communication and inefficient documentation of insights. Amit Sheinholtz, Senior Associate User Experience Consultant and Elisa del Galdo, Head of Customer Experience discuss common pitfalls of the negative insight lifecycle and how to avoid them.